This Article Full Text Full Text (PDF) All Versions of this Article: 39/7/2174    most recent STROKEAHA.107.509588v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Muir, K. W. Search for Related Content PubMed PubMed Citation Articles by Muir, K. W. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Blood Thinners Related Collections Antiplatelets Other Stroke Treatment - Medical

(Stroke. 2008;39:2174.)
© 2008 American Heart Association, Inc.

Emerging Therapies

The PREVAIL Trial and Low-Molecular-Weight Heparin for Prevention of Venous Thromboembolism

From the Division of Clinical Neurosciences, University of Glasgow, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK.

Correspondence to Keith W. Muir, MD, FRCP, Institute of Neurological Sciences, Southern General Hospital, Glasgow G51 4TF, UK. E-mail k.muir@clinmed.gla.ac.uk

Marc Fisher MD Kennedy Lees MD Section Editors:

Key Words: antiplatelet agents • venous thromboembolism

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Patients with stroke are at high risk for venous thromboembolism. Studies of the natural history in the era before widespread use of antiplatelet agents or physical preventive measures reported an incidence of deep vein thrombosis (DVT) of over 50% within the first days.¹ A lower incidence might be expected with more aggressive routine acute treatment, including early use of antiplatelet agents, early mobilization, and graduated compression stockings, but the combined control groups of randomized, controlled trials (RCTs) predominantly undertaken in the 1990s still reported an incidence of 37% when DVT was specifically sought.² Older studies found the incidence of pulmonary embolism (PE) after stroke to be 10% to 20% and to account for up to 10% of all fatalities (including cases in ambulant patients).³ In contrast, symptomatic PE is consistently rarely reported in RCTs in stroke, occurring in just 0.7% of randomized subjects in the control group of trials comparing heparins with antiplatelet therapy.⁴ However, clinical recognition of PE remains poor. Half of all PEs in one series presented as sudden death.⁵ Clinically unrecognized PE is also common, with up to 50% of surgical patients with proximal DVT having abnormal ventilation–perfusion lung scans.⁶ Even if PE is rare, postthrombotic syndrome resulting from venous valvular incompetence causes pain, swelling, and skin changes, including varicose eczema, and may affect over 20% of those with symptomatic DVT within 2 years.

The effectiveness of low-dose unfractionated heparin for prevention of VTE was established in the late 1970s, predominantly in surgical patients but also in . . . [Full Text of this Article]